Objective To observe and analyze the curative effect of seretide in the treatment of bronchial asthma. Methods 116 patients with bronchial asthma were randomly divided into two groups. Two groups of patients were given away from allergic source, anti-infection, spasmolysis, asthma and other symptomatic treatment. The control group, consisting of 58 patients, was given beclomethasone dipropionate 250μg, 1 times 1, 2 times a day, inhalation therapy. The observation group, consisting of 58 patients, was given seretide, a 1-2 ceiling, 2 times daily, inhalation therapy. Both groups were treated for three months. Results The two groups after treatment FEV1, MMEF, PEF compared with before treatment, were significantly decreased (P < 0.01 or P < 0.05); After treatment between two groups, the treatment group was significantly better than the control group (P<0.05);The observation group was significantly better than the control group in the total effective rate after treatment (P<0.05). Conclusion Seretide which can significantly improve the clinical symptoms and lung function is effective in the treatment of bronchial asthma.%目的：探讨舒利迭治疗支气管哮喘的临床疗效。方法116例支气管哮喘患者，随机分为对照组和观察组，两组均58例。两组患者入院后均给予脱离过敏源、抗感染、解痉、平喘等对症治疗。对照组在此治疗的基础上给予丙酸倍氯米松250μg，1次1吸，每日2次，吸入治疗；观察组在对照组的基础上给予舒利迭，1次1～2吸，每日2次，吸入治疗。1个月为1个疗程，两组患者均治疗3个疗程。结果两组治疗后FEV1、MMEF、PEF与治疗前相比较，均明显降低（P＜0.01或P＜0.05）；治疗后两组组间比较，治疗组明显优于对照组（P＜0.05）；治疗后两组总体有效率比较，治疗组明显优于对照组（P＜0.05）。结论舒利迭治疗支气管哮喘，可以明显改善临床症状及肺功能指标，疗效显著。
展开▼
